NOD2

Across TCGA pan-cancer cohorts, NOD2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NOD2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NOD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

ACC, UCEC, and ESCA are the cancer types where NOD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
UCEC	DFS	Median	All	0.845	0.630	.006	14	view →
ESCA	OS	Median	II,III,IV	0.109	0.931	<.001	12	view →
STAD	OS	Median	II,III,IV	1.000	0.404	.028	9	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	9	view →
BRCA	OS	Median	III,IV	0.676	0.906	.007	8	view →
PRAD	DFS	Median	All	0.085	0.774	.006	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NOD2–ACC (DFS)

Open the ACC breakdown →